ES2484340T3 - Anticuerpos anti hsp70 terapéuticos y diagnósticos - Google Patents

Anticuerpos anti hsp70 terapéuticos y diagnósticos Download PDF

Info

Publication number
ES2484340T3
ES2484340T3 ES09003983.5T ES09003983T ES2484340T3 ES 2484340 T3 ES2484340 T3 ES 2484340T3 ES 09003983 T ES09003983 T ES 09003983T ES 2484340 T3 ES2484340 T3 ES 2484340T3
Authority
ES
Spain
Prior art keywords
dsmz
hybridoma
november
seq
deposited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09003983.5T
Other languages
English (en)
Inventor
Gabriele Multhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multimmune GmbH
Original Assignee
Multimmune GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2484340(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Multimmune GmbH filed Critical Multimmune GmbH
Application granted granted Critical
Publication of ES2484340T3 publication Critical patent/ES2484340T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un anticuerpo o un fragmento de unión a antígeno del mismo que i) se une a un epítope localizado extracelularmente de la Hsp70 unida a membrana sobre las células tumorales, en el que dicho epítope comprende o consta de la secuencia de aminoácidos NLLGRFEL (SEC ID N.º: 1) o TKDNNLLGRFELSG (SEC ID N.º: 2); y ii) comprende las CDR determinadas según Kabat del anticuerpo monoclonal cmHsp70.1 tal y como lo producía el hibridoma cmHsp70.1, depositado en la DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Alemania) el 14 de noviembre de 2003, y al que se asignó el número de acceso de la DSM ACC2629, o cmHsp70.2, tal y como lo produce el hibridoma cmHsp70.2, depositado en la DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) el 14 de noviembre de 2003 y al que se asignó el número de acceso de la DSM ACC2630.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20

Claims (1)

  1. imagen1
    imagen2
ES09003983.5T 2003-12-05 2004-12-06 Anticuerpos anti hsp70 terapéuticos y diagnósticos Expired - Lifetime ES2484340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03028144 2003-12-05
EP03028144 2003-12-05

Publications (1)

Publication Number Publication Date
ES2484340T3 true ES2484340T3 (es) 2014-08-11

Family

ID=34639281

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09003983.5T Expired - Lifetime ES2484340T3 (es) 2003-12-05 2004-12-06 Anticuerpos anti hsp70 terapéuticos y diagnósticos
ES04803556T Expired - Lifetime ES2324538T3 (es) 2003-12-05 2004-12-06 Anticuerpos anti-hsp terapeuticos y de diagnostico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04803556T Expired - Lifetime ES2324538T3 (es) 2003-12-05 2004-12-06 Anticuerpos anti-hsp terapeuticos y de diagnostico.

Country Status (8)

Country Link
US (3) US7700737B2 (es)
EP (2) EP1706423B8 (es)
JP (2) JP4898452B2 (es)
AT (1) ATE426617T1 (es)
CY (2) CY1109125T1 (es)
DE (1) DE602004020266D1 (es)
ES (2) ES2484340T3 (es)
WO (1) WO2005054295A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2484340T3 (es) * 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
DK3578195T5 (da) 2008-06-26 2024-06-10 Zevra Denmark As Anvendelse af Hsp70 som regulator af enzymatisk aktivitet
EP2580232A1 (en) * 2010-06-08 2013-04-17 National University of Ireland, Galway Manipulation of hsp70 and ire1alpha protein interactions
WO2012072082A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
HK1204261A1 (en) 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
HUE054957T2 (hu) 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
US20180002435A1 (en) 2015-01-26 2018-01-04 Cellectis mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
WO2016120325A1 (en) 2015-01-27 2016-08-04 Klinikum Rechts Der Isar Der Technischen Universität München Quantitative assay for heat shock protein 70 (hsp70) protein in body fluids
KR102588816B1 (ko) * 2016-02-02 2023-10-13 엠. 테크닉 가부시키가이샤 미립자 분산액의 정밀 개질 방법
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
CA3287846A1 (en) 2016-04-29 2025-11-29 Zevra Denmark A/S Arimoclomol for treating glucocerebrosidase associated disorders
EP3675877A1 (en) 2017-08-31 2020-07-08 Multimmune GmbH Hsp70 based combination therapy
CA3172949A1 (en) * 2020-03-27 2021-09-30 Robert Z. Orlowski Monoclonal antibodies targeting hsp70 and therapeutic uses thereof
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
WO2024242202A1 (ja) * 2023-05-25 2024-11-28 公立大学法人大阪 抗Ｈｓｐ７０抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
DE69321962T2 (de) 1992-08-21 1999-07-01 Biogen Inc Von tat abgeleitete transportpolypeptide
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6458933B1 (en) 1998-05-20 2002-10-01 Immunomedics, Inc. Therapeutic using a bispecific antibody
US20040180046A1 (en) 2000-04-26 2004-09-16 Jeff Himawan Bispecific molecules and uses thereof
ES2326114T3 (es) * 2000-09-13 2009-10-01 Multimmune Gmbh Un peptido de hsp70 estimulador de la actividad de las celulas asesinas naturales (nk) y los usos del mismo.
AU2003227610A1 (en) * 2002-04-12 2003-10-27 Multimmune Gmbh Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents
ES2484340T3 (es) * 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
US7943740B2 (en) * 2003-12-05 2011-05-17 Multimmune Gmbh Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases

Also Published As

Publication number Publication date
EP1706423B1 (en) 2009-03-25
CY1116052T1 (el) 2017-02-08
DE602004020266D1 (de) 2009-05-07
US8440188B2 (en) 2013-05-14
CY1109125T1 (el) 2014-07-02
EP1706423B8 (en) 2009-07-08
WO2005054295A2 (en) 2005-06-16
ES2324538T3 (es) 2009-08-10
WO2005054295A3 (en) 2006-12-28
US20070231337A1 (en) 2007-10-04
EP1706423A2 (en) 2006-10-04
JP4898452B2 (ja) 2012-03-14
JP2012006933A (ja) 2012-01-12
JP2008502314A (ja) 2008-01-31
ATE426617T1 (de) 2009-04-15
EP2070947A1 (en) 2009-06-17
JP5414750B2 (ja) 2014-02-12
WO2005054295A8 (en) 2005-08-18
US20100143356A1 (en) 2010-06-10
US20120087931A1 (en) 2012-04-12
EP2070947B1 (en) 2014-06-11
US7700737B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
ES2484340T3 (es) Anticuerpos anti hsp70 terapéuticos y diagnósticos
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
SA523440043B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
PE20070183A1 (es) Anticuerpos monoclonales anti-trkb
PE20120815A1 (es) Anticuerpos anti il-17f y metodos de uso de los mismos
RU2011134500A (ru) Антитела и иммуноконъюгаты и их применения
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
NZ616992A (en) Anti-ilt7 antibody
ES2628108T3 (es) Anticuerpos multiespecíficos
HRP20150641T1 (hr) Anti -cd38 humana antitijela i njihove uporabe
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
PE20121023A1 (es) Anticuerpos e inmunoconjugados
AR059432A1 (es) Anticuerpos anti-fgf19 y metodos que usan estos
CO6331344A2 (es) Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
PE20120553A1 (es) Anticuerpos anti-fgfr3
CA2603414A1 (en) Anti-cd20 monoclonal antibody
NZ548325A (en) Mutants of anti-CD40 antibody
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
RU2012128343A (ru) АНТИ-С4.4а АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
PE20221337A1 (es) Anticuerpos trem2 y usos de estos
NZ582619A (en) Humanized anti-fgf19 antagonists and methods using same
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
HRP20030805B1 (hr) Rekombinantna protutijela povezana s gangliozidima i njihova upotreba u dijagnostici i liječenju tumora